Immunology · IL-23Regulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for SKYRIZI (Risankizumab)

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:31:35 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for SKYRIZI signifies a potential expansion of its label, which could enhance AbbVie's market position in the immunology sector. This development necessitates proactive strategic planning to address shifts in competitive dynamics and market opportunities. Regulatory context from FDA (FDA AP — SKYRIZI (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential shifts in market dynamics and consider strategic positioning for SKYRIZI's expanded use. The strongest clinical anchor is Local Methotrexate Injections for the Treatment of Nail Psoriasis (ClinicalTrials.gov), entity match (psoriasis). In Immunology · IL-23, 8 regulatory and 1 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — entity match (immunology). This acceptance may enhance AbbVie's competitive position in the IL-23 inhibitor market, particularly against other therapies targeting similar indications.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SKYRIZI (SUPPL) (FDA). Entity match (abbvie). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and any additional indications will need to be closely monitored.

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

An expanded label for SKYRIZI could lead to increased market share and revenue, particularly as it competes with other therapies in the IL-23 inhibitor space.
Portfolio teams should prepare for potential shifts in market dynamics and consider strategic positioning for SKYRIZI's expanded use.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's review process and any announcements regarding additional indications for SKYRIZI.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — LUPRON (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — VENCLEXTA (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — LINZESS (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — DECNUPAZ (ORIG)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
FDA AP — RINVOQ LQ (SUPPL)
FDAhigh relevance
Entity match (abbvie)
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Local Methotrexate Injections for the Treatment of Nail Psoriasis
ClinicalTrials.govhigh relevance
Entity match (psoriasis)
FDA document
View source
Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Discovering Determinants of Food Intake by Application of Artificial Intelligence to Complex, High-Dimensional Data
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cachexia and Gut Microbiota in Patients With Breast Cancer Receiving Home Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Entity match (immunology)

Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie
SKYRIZI
Psoriasis
Immunology

Commercial impact

medium

An expanded label for SKYRIZI could lead to increased market share and revenue, particularly as it competes with other therapies in the IL-23 inhibitor space.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and any additional indications will need to be closely monitored.

What to watch

Monitor the timeline for the FDA's review process and any announcements regarding additional indications for SKYRIZI.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.